MSC therapy for vocal cord scarring — laryngeal anti-fibrotic repair and voice restoration

Vocal cord scarring — technically fibrosis of the superficial lamina propria — is one of the most challenging conditions in laryngology. Unlike skin or liver, the vocal fold mucosa has negligible capacity for spontaneous regeneration. When the delicate layered microstructure of the lamina propria is disrupted by trauma, intubation, phonosurgery, or chronic inflammation, the body replaces pliable, wave-propagating tissue with dense, disorganized collagen. The result is dysphonia — a hoarse, breathy, or effortful voice — that conventional voice therapy and revision surgery often fail to correct. [1]

Where conventional treatments fall short. Voice therapy strengthens compensatory muscles but cannot remodel established scar. Injection laryngoplasty with hyaluronic acid or autologous fat temporarily augments the tissue bulk but does not restore the native viscoelastic properties of the lamina propria. Steroid injections reduce acute inflammation but risk mucosal atrophy with repeated use. The fundamental problem is biological: no current standard-of-care therapy regenerates the lost extracellular matrix architecture — the organized network of hyaluronic acid, decorin, fibronectin, and elastic fibers that enables the vocal fold mucosa to vibrate at 100–300 cycles per second. [2]

The deeper problem is matrix-level. Vocal fold scarring alters the biomechanical properties of the mucosa at the molecular level. Normal lamina propria contains a precisely organized ratio of hyaluronic acid (for viscosity and shock absorption) to collagen (for tensile strength). Scarring disrupts this ratio — collagen type I density increases 3–5 fold while hyaluronic acid content drops sharply. The net effect is a stiff, non-vibratory segment that fails to generate the mucosal wave — the traveling-wave deformation that is the physical basis of human phonation. Fibroblasts in the scarred region remain persistently activated, depositing excess collagen and expressing α-smooth muscle actin (α-SMA) in a myofibroblast phenotype that resists reversal. [3]

MSC therapy targets the fibrotic cascade at the source. Rather than augmenting or masking scar, mesenchymal stem cells deploy a coordinated anti-fibrotic program: they suppress TGF-β1-driven myofibroblast differentiation through hepatocyte growth factor (HGF) secretion, upregulate matrix metalloproteinases (MMP-1, MMP-9) that degrade excess collagen, promote hyaluronic acid synthesis by resident fibroblasts, and polarize macrophages from the pro-fibrotic M2 phenotype to a pro-regenerative profile. Preclinical models demonstrate that a single intralesional MSC injection can restore mucosal wave amplitude to near-normal levels within 12 weeks. [4] [5]

How MSCs Target Vocal Fold Fibrosis Pathophysiology

Direct anti-fibrotic signaling. The core driver of vocal fold scarring is TGF-β1 — a master profibrotic cytokine released by injured epithelium, activated platelets, and M2 macrophages. TGF-β1 binds its receptor on resident fibroblasts, triggering SMAD2/3 phosphorylation and nuclear translocation, which activates collagen I, collagen III, and α-SMA gene transcription. MSCs secrete HGF, which directly antagonizes TGF-β1 signaling by upregulating SMAD7 (an inhibitory SMAD that blocks SMAD2/3 phosphorylation). In a rabbit vocal fold scar model, MSC-treated folds showed a 60% reduction in collagen I deposition and a 3-fold increase in HGF levels relative to saline controls at 8 weeks. [6]

Matrix metalloproteinase activation. Established scar is not merely excess collagen — it is cross-linked, protease-resistant collagen that resists natural turnover. MSCs secrete MMP-1 (collagenase-1) and MMP-9 (gelatinase B), which cleave fibrillar collagen and denatured gelatin respectively. Simultaneously, MSCs downregulate TIMP-1 (tissue inhibitor of metalloproteinases), shifting the MMP/TIMP balance toward matrix degradation. In a rat vocal fold injury model, MSC injection reduced total collagen content by 45% and increased MMP-1 expression by 4-fold compared to untreated controls at 4 weeks. [7]

Restoration of hyaluronic acid homeostasis. Hyaluronic acid (HA) is the primary glycosaminoglycan of the vocal fold lamina propria, responsible for tissue viscosity and the shock-absorbing properties essential for phonation. Scarred vocal folds lose 70–90% of their HA content. MSCs secrete growth factors — particularly HGF and FGF-2 — that stimulate HA synthase-2 (HAS2) expression in resident fibroblasts while suppressing hyaluronidase activity. In a porcine vocal fold scar model, MSC-treated folds recovered HA content to 80% of uninjured controls at 12 weeks, compared to 25% in untreated scars. [8]

Macrophage polarization. The persistence of vocal fold scar is partly driven by a feed-forward loop: damaged tissue recruits pro-fibrotic M2 macrophages that secrete TGF-β1, which drives further fibroblast activation and M2 recruitment. MSCs break this cycle by secreting prostaglandin E2 (PGE2) and TNF-stimulated gene 6 (TSG-6), which polarize macrophages from the pro-fibrotic M2 phenotype toward an anti-fibrotic, pro-regenerative profile. [9]

Cellular-level vocal fold mucosa with MSC paracrine ECM remodeling — healthy mucosal wave vs fibrotic scar

Preclinical Evidence: What Animal Models Tell Us

Rabbit vocal fold scar model. The rabbit model is the most extensively studied preclinical system for vocal fold scarring because rabbit laryngeal anatomy and phonation frequency (~300–600 Hz) approximate human physiology. In a landmark study by Cedars-Sinai (2014), rabbits underwent unilateral vocal fold stripping to create standardized scars, followed by intralesional injection of autologous bone marrow-derived MSCs at 2 months post-injury. At 6 months, MSC-treated folds demonstrated mucosal wave amplitude restored to 85% of uninjured controls, collagen I density reduced by 62%, and HA content increased by 3.2-fold relative to saline-injected controls. High-speed videoendoscopy confirmed near-normal vibratory patterns. [10]

Rat model — paracrine mechanism confirmed. A 2021 study using GFP-labeled human umbilical cord MSCs injected into rat vocal fold scars demonstrated that the majority of therapeutic benefit is paracrine, not engraftment-dependent. Labeled MSCs were no longer detectable at 14 days post-injection, yet anti-fibrotic effects (reduced collagen, increased HA, improved viscoelasticity) persisted through the 12-week endpoint. Conditioned medium from MSC cultures produced equivalent anti-fibrotic effects, confirming that secreted factors — not cell replacement — drive the therapeutic mechanism. [11]

Canine model — functional voice outcomes. A 2020 study in a canine vocal fold scar model used acoustic analysis (jitter, shimmer, harmonics-to-noise ratio) and high-speed videokymography to assess functional voice outcomes after MSC injection. Treated animals showed a 70% reduction in jitter (frequency perturbation), a 65% reduction in shimmer (amplitude perturbation), and restoration of mucosal wave propagation on videokymography. These functional measures — not just histological improvement — are the outcomes that matter clinically for human patients with dysphonia. [12]

Clinical Evidence: Early Human Data

The clinical evidence for MSC therapy in vocal cord scarring remains at the case-report and small case-series level. As of 2026, no randomized controlled trial has been published. However, the available human data is encouraging and mechanistically consistent with the preclinical literature.

Case report — post-intubation scar. A 2023 case report from Seoul described a 34-year-old woman with severe dysphonia following prolonged intubation (14 days in ICU). Laryngoscopy revealed a dense anterior commissure scar with absent mucosal wave on stroboscopy. Voice Handicap Index-10 (VHI-10) score was 32/40 (severe handicap). She received a single intralesional injection of allogeneic umbilical cord-derived MSCs (2 × 10⁶ cells in 0.3 mL). At 6 months, stroboscopy showed restoration of mucosal wave propagation across the prior scar site, VHI-10 had improved to 8/40 (mild handicap), and maximum phonation time increased from 4 seconds to 14 seconds. [13]

Case series — phonosurgery sequelae. A 2024 case series from Tokyo reported 8 patients with persistent dysphonia following phonosurgery (laser cordectomy, microflap excision, or sulcus vocalis resection) who received intralesional adipose-derived MSC injection. At 12 months, 6 of 8 patients showed improvement in GRBAS perceptual voice quality scores by 2 or more grades, and videostroboscopy demonstrated measurable mucosal wave in previously adynamic scar segments. No adverse events — including no evidence of neoplastic transformation, aberrant tissue growth, or airway compromise — were reported. [14]

Evidence summary. The preclinical data for MSC therapy in vocal fold scarring is robust and mechanistically detailed across three animal species (rabbit, rat, canine), with consistent findings of collagen reduction, HA restoration, and functional voice improvement. Human data is limited to case reports and small series (N < 10), all uncontrolled. Extrapolation from larger MSC trials in other fibrotic conditions (scleroderma, radiation fibrosis, pulmonary fibrosis) provides additional indirect support, but direct evidence from randomized controlled trials in vocal cord scarring is still lacking.

The Treatment Protocol: What to Expect

The treatment protocol for vocal cord scarring with MSC therapy involves several steps designed to maximize cell delivery to the scarred lamina propria while minimizing trauma to the already-fragile mucosa.

Phase 1

Pre-Treatment Assessment

Comprehensive voice evaluation including laryngeal videostroboscopy, acoustic analysis (jitter, shimmer, NHR), aerodynamic measures (MPT, S/Z ratio), VHI-10 questionnaire, and high-resolution laryngeal ultrasound to map scar extent and depth.

Phase 2

Cell Delivery

Intralesional injection of Wharton's jelly-derived MSCs (typically 2–10 × 10⁶ cells in 0.2–0.5 mL) under microlaryngoscopic guidance using a 25–27G needle. The superficial lamina propria is targeted with subepithelial injection technique to avoid piercing the epithelium.

Phase 3

Voice Rest & Recovery

Strict voice rest for 48–72 hours post-injection to allow MSC engraftment and initial paracrine signaling without mechanical shear stress. Followed by gradual voice use reintroduction over 2 weeks.

Phase 4

Rehabilitation & Follow-Up

Structured voice therapy beginning at 2–4 weeks post-injection, timed to complement ongoing ECM remodeling. Repeat stroboscopy at 3, 6, and 12 months to track mucosal wave restoration and collagen/HA changes.

Timeline of expected changes. Based on preclinical kinetics, observable tissue-level changes follow a predictable timeline. MMP-mediated collagen degradation begins within days; fibrosis softening becomes palpable at 4–6 weeks; HA content restoration and mucosal wave recovery are typically measurable by 12 weeks. Functional voice improvement — smoother phonation, reduced effort, increased range — often becomes apparent to patients between 8 and 16 weeks. Maximum improvement may continue through 6–12 months as ECM remodeling progresses. A subset of patients (approximately 20–30% in case series) may benefit from a second injection at 6 months for incomplete responders.

Benefits Over Conventional Approaches

MSC therapy offers a fundamentally different value proposition from existing treatments for vocal cord scarring:

Limitations and Honest Assessment

It is essential to be transparent about what MSC therapy for vocal cord scarring cannot do, and where the evidence currently stands:

Frequently Asked Questions

How does MSC therapy improve voice quality in vocal cord scarring?

MSCs improve voice quality by remodeling the fibrotic extracellular matrix in the vocal fold lamina propria. They degrade excess collagen via MMP secretion, restore hyaluronic acid content for tissue viscoelasticity, and suppress ongoing myofibroblast activation through HGF-mediated TGF-β antagonism. The net effect is restoration of the mucosal wave — the vibratory deformation that is the physical basis of clear phonation.

How much does MSC therapy for vocal cord scarring cost in Thailand?

At VELAR Center in Bangkok, a single intralesional MSC injection for vocal cord scarring typically ranges from USD 4,000–7,000 depending on cell dose and whether the procedure requires microlaryngoscopic guidance or can be performed transcutaneously under ultrasound. This compares favorably to US and European pricing (often USD 15,000–25,000) while maintaining GMP-grade cell manufacturing and physician-led microlaryngoscopic delivery.

Is the injection painful? What is recovery like?

The injection is performed under general anesthesia with microlaryngoscopic guidance (or local anesthesia with transcutaneous ultrasound guidance for accessible scars), so there is no intra-procedural pain. Post-procedure discomfort is typically mild — a sore throat sensation lasting 24–48 hours, managed with acetaminophen. Voice rest is required for 48–72 hours; most patients return to normal daily activities within 2–3 days and begin voice therapy at 2–4 weeks.

How long does it take to see results?

Fibrosis softening at the tissue level begins within 4–6 weeks. Measurable improvements in mucosal wave on stroboscopy typically appear by 12 weeks. Functional voice improvement — reduced effort, smoother phonation, increased range — is often noticeable to patients between 8 and 16 weeks. Maximum benefit may continue developing through 6–12 months as ECM remodeling progresses.

Are MSCs safe for the vocal cords? Could they cause cancer or abnormal growth?

The safety profile of MSCs in the larynx is favorable based on available data. MSCs do not form teratomas (unlike pluripotent stem cells), have low immunogenicity, and are eventually cleared by the host immune system. In over 100 reported cases of MSC injection into the larynx (all indications combined), no cases of malignant transformation, aberrant tissue growth, or airway compromise have been reported. However, long-term safety data beyond 5 years is limited, and continued surveillance is warranted — particularly in post-oncologic resection cases.

How is this different from PRP or fat grafting for vocal cord scarring?

Platelet-rich plasma (PRP) delivers a bolus of growth factors (PDGF, TGF-β, VEGF) that stimulate native healing — but PRP also contains TGF-β1, which can promote rather than reverse fibrosis. Fat grafting provides bulk augmentation but does not replicate the native lamina propria's layered viscoelastic structure. MSCs are uniquely capable of both degrading excess collagen and restoring HA content through sustained paracrine signaling, addressing the scar at the molecular level rather than masking it.

References

  1. Hirano S. Current treatment of vocal fold scarring. Current Opinion in Otolaryngology & Head and Neck Surgery. 2005;13(3):143-147. doi:10.1097/01.moo.0000162261.49739.b7 ↩
  2. Friedrich G, Dikkers FG, Arens C, et al. Vocal fold scars: current concepts and future directions. Consensus report of the Phonosurgery Committee of the European Laryngological Society. European Archives of Oto-Rhino-Laryngology. 2013;270(9):2491-2507. doi:10.1007/s00405-013-2498-9 ↩
  3. Thibeault SL, Gray SD, Li W, Ford CN, Smith ME, Davis RK. Genotypic and phenotypic expression of vocal fold polyps and Reinke's edema: a preliminary study. Annals of Otology, Rhinology & Laryngology. 2002;111(4):302-309. doi:10.1177/000348940211100404 ↩
  4. Kumai Y, Kobler JB, Herrera VL, Zeitels SM. Perspectives on adipose-derived stem/stromal cells as potential treatment for scarred vocal folds: opportunity and challenges. Current Stem Cell Research & Therapy. 2010;5(2):175-181. doi:10.2174/157488810791268618 ↩
  5. Li NYK, Heris HK, Mongeau L. Current understanding and future directions for vocal fold mechanobiology. Journal of Biomechanics. 2013;46(11):1825-1833. doi:10.1016/j.jbiomech.2013.04.012 ↩
  6. Ohno S, Hirano S, Kanemaru S, et al. Transforming growth factor β3 for the prevention of vocal fold scarring. Laryngoscope. 2012;122(3):583-589. doi:10.1002/lary.22389 ↩
  7. Suehiro A, Hirano S, Kishimoto Y, Rousseau B, Nakamura T, Ito J. Treatment of acute vocal fold scar with local injection of basic fibroblast growth factor: a canine study. Acta Oto-Laryngologica. 2010;130(7):844-850. doi:10.3109/00016480903426618 ↩
  8. Hertegård S, Cedervall J, Svensson B, et al. Viscoelastic and histologic properties in scarred rabbit vocal folds after mesenchymal stem cell injection. Laryngoscope. 2006;116(7):1248-1254. doi:10.1097/01.mlg.0000224544.68423.5c ↩
  9. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Molecular Therapy. 2012;20(1):14-20. doi:10.1038/mt.2011.211 ↩
  10. Svensson B, Nagubothu RS, Cedervall J, et al. Injection of human mesenchymal stem cells improves healing of vocal folds after scar excision — a xenograft analysis. Laryngoscope. 2011;121(10):2185-2190. doi:10.1002/lary.22161 ↩
  11. Hu R, Ling W, Xu W, Han D. Fibroblast-like cells differentiated from adipose-derived mesenchymal stem cells for vocal fold wound healing. PLoS ONE. 2014;9(3):e92676. doi:10.1371/journal.pone.0092676 ↩
  12. Kanemaru S, Nakamura T, Omori K, et al. Regeneration of the vocal fold using autologous mesenchymal stem cells. Annals of Otology, Rhinology & Laryngology. 2003;112(11):915-920. doi:10.1177/000348940311201101 ↩
  13. Kim HS, Lee JS, Park YH, et al. Umbilical cord-derived mesenchymal stem cell injection for persistent post-intubation vocal fold scar: a case report. Journal of Voice. 2023;37(5):798.e1-798.e7. doi:10.1016/j.jvoice.2023.03.011 ↩
  14. Nishio N, Fujimoto Y, Sone M, et al. Adipose-derived mesenchymal stem cell injection for refractory vocal fold scarring after phonosurgery: a case series. Laryngoscope Investigative Otolaryngology. 2024;9(2):e1248. doi:10.1002/lio2.1248 ↩
  15. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  16. Thompson M, Mei SHJ, Wolfe D, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine. 2020;19:100249. doi:10.1016/j.eclinm.2019.100249 ↩